EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer

Jieran Long, Xuefei Li, Lin Wu iD, Guohua Yu, Aimin Zang, Yanqiu Zhao, Jinsheng Shi, Ligong Nie, Xuan Zhao, Jian Fang iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70059 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jieran Long und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Beijing University Cancer Hospital, Beijing, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Irinotecan, Polyethylene Glycols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the safety, tolerability, and preliminary efficacy of multiple doses of pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients.

Methods

According to the “3 + 3” dose‐escalation principle, patients received intravenous JK1201I at 180 or 220 mg/m 2 once every 3 weeks for four cycles. Progression‐free survival (PFS), overall survival (OS), median progression‐free survival (mPFS), and median overall survival (mOS) were evaluated. The Kaplan–Meier method was used to analyze PFS and overall OS. Brookmeyer and Crowley's method was used for mPFS and mOS.

Results

This study included 29 patients with stage III–IV SCLC (stage IIIa, n = 1; stage IIIb, n = 1; and stage IV, n = 27). Of these, 26 patients were enrolled in the 180 mg/m 2 dose group, and 3 patients were enrolled in the 220 mg/m 2 dose group. No dose‐limiting toxicity (DLT) was noted during the first 28 days of treatment. Grade 3 or higher adverse events were recorded in the 180 mg/m 2 group, including diarrhea (11.5%, 3/26), neutropenia (7.7%, 2/26), and leukopenia (7.7%, 2/26). In the 220 mg/m 2 group, one patient (33.3%, 1/3) experienced neutropenia or leukopenia. In the 180 mg/m 2 group, 38.5% (10/26) of patients achieved an objective response rate (ORR), with a disease control rate (DCR) of 73.1% (19/26). The mPFS and mOS were 3.4 and 12.1 months, respectively. In the 220 mg/m 2 group, one patient had stable disease, and one had progressive disease (PD). The ORR, DCR, mPFS, and mOS were 0% (0/3) and 33.3% (1/3), 2.7 months and 2.7 months, respectively.

Conclusion

JK1201I exhibits promising efficacy and relatively low toxicities as a second‐line monotherapy for SCLC, warranting further large‐scale clinical studies to evaluate its efficacy in greater detail.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsIrinotecanPolyethylene GlycolsHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeNeoplasm StagingProgression-Free Survival

Stichwörter der Autor:innen

overall survivalsafetysecond‐line monotherapysmall‐cell lung cancer

Substanzen

IrinotecanPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Beijing University Cancer Hospital, Beijing, China.
  • Department of Clinical Medicine and Pharmacology, JenKemTechnology Co., Ltd. (Tian Jin), Tianjin, China.
  • Thoracic Medicine Department, Hunan Cancer Hospital, Changsha, Hunan, China.
  • Medicine Oncology Department, Weifang People's Hospital, Weifang, Shandong, China.
  • Internal Medicine Oncology Ward, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
  • Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, Henan, China.

ORCID-Profile: Lin Wu, Jian Fang

Zitieren

APA

Long, J., Li, X., Wu, L., Yu, G., Zang, A., Zhao, Y., Shi, J., Nie, L., Zhao, X., & Fang, J. (2024). Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70059

Vancouver

Long J, Li X, Wu L, Yu G, Zang A, Zhao Y, et al. Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70059

BibTeX
@article{Long2024,
  author = {Long, Jieran and Li, Xuefei and Wu, Lin and Yu, Guohua and Zang, Aimin and Zhao, Yanqiu and Shi, Jinsheng and Nie, Ligong and Zhao, Xuan and Fang, Jian},
  title = {Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70059}
}
Kostenlos starten →